Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics

doi:10.5501/wjv.v4.i3.169

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7861)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-1) series.

Item

Count

PDF

480

WORD

330

HTML

3343

Tables (1-1)

518

Sum=4671

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1171

Download

2021

Sum=3192

Aug 12, 2015 (publication date) through Feb 11, 2026

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Editorial

World J Virology. Aug 12, 2015; 4(3): 169-177
Published online Aug 12, 2015. doi: 10.5501/wjv.v4.i3.169

Can antiretroviral therapy be tailored to each human immunodeficiency virus-infected individual? Role of pharmacogenomics

Victor Asensi, Julio Collazos, Eulalia Valle-Garay

Victor Asensi, Infectious Diseases-HIV Unit, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, 33013 Oviedo, Spain

Julio Collazos, Infectious Diseases Unit, Hospital de Galdácano, 48960 Vizcaya, Spain

Eulalia Valle-Garay, Biochemistry and Molecular Biology Department, Oviedo University School of Medicine, 33006 Oviedo, Spain

Author contributions: All authors contributed to this paper.

Conflict-of-interest statement: The authors do not have any conflict of interest related to this paper.

Correspondence to: Victor Asensi, MD, PhD, Infectious Diseases-HIV Unit, Hospital Universitario Central de Asturias, Oviedo University School of Medicine, Avenida de Roma s/n, 33013 Oviedo, Spain. vasensia@gmail.com

Telephone: +34-985-108000-36442

Received: January 15, 2015
Peer-review started: January 16, 2015
First decision: April 27, 2015
Revised: May 8, 2015
Accepted: June 9, 2015
Article in press: June 11, 2015
Published online: August 12, 2015
Processing time: 210 Days and 9.4 Hours

Core Tip

Core tip: Pharmacogenetics may play an important role in the near future for the treatment of human immunodeficiency virus-infection, as exemplified by the HLAB*5701 genotyping to prevent the abacavir-associated hypersensitivity reaction. Diverse other single nucleotide polymorphisms have been described as related to certain pharmacokinetic characteristics and adverse effects of antiretroviral drugs. In this Editorial we summarize the current knowledge on this rapidly evolving field.